RSNA 2025: Hologic Shares New Evidence on AI-Powered Mammography Solutions 

New data on Hologic’s breast cancer detection technologies is being presented this week at the Radiological Society of North America (RSNA) Annual Meeting in Chicago (Nov. 30-Dec. 4).

“At Hologic, we’re committed to advancing our technologies to support women at every stage of the breast health continuum, and real-world studies are a critical part of that,” said Mark Horvath, president of Breast & Skeletal Health Solutions at Hologic. “Artificial intelligence is increasingly becoming a critical tool in mammography, and we are encouraged to see data from multiple studies underscoring its potential to help radiologists work more efficiently without sacrificing quality.”

In a study led by Dr. Manisha Bahl, M.D., associate medical director of Quality at Mass General Brigham and associate professor of Radiology at Harvard Medical School, researchers at Massachusetts General Hospital evaluated Hologic’s 3DQuorum imaging technology.

Based on more than 160,000 screening mammography exams, the retrospective study compared cancer detection rates before and after adopting 3DQuorum imaging technology, which uses artificial intelligence (AI) to reduce the number of 3D imaging “slices” radiologists need to review without compromising image quality, sensitivity or accuracy.^1,2 In the simplest terms, the technology is comparable to condensing a 60-page book into a 10-page summary that retains all relevant information and highlights key findings.

The study found no significant difference in cancer detection rates after implementation of 3DQuorum. With ongoing radiologist shortages, these results suggest the technology’s potential to streamline radiologists’ workflows and save valuable time while maintaining high effectiveness in detecting cancers.

“AI holds boundless potential in healthcare that we are only beginning to tap into, with a wide range of applications that can improve patient care,” Dr. Bahl said. “In breast cancer screening, technologies like 3DQuorum help radiologists work more efficiently while still delivering the same care to every woman. By streamlining the review process, AI allows us to focus our attention where it matters most: finding cancers early and supporting each patient with confidence.”

Another study, led by Professor Yan Chen, Ph.D., chair of Digital Screening and head of the Digital Cancer Screening Research Group at the University of Nottingham, U.K., examined Hologic’s Genius AI Detection solution compared with radiologists. In this study, 108 radiologists from the United Kingdom and United States reviewed 75 challenging breast cancer cases, and the AI system assessed the same cases.

Overall, the AI technology performed similarly to radiologists. It detected more cancers but also showed lower specificity, meaning it could flag more false positives. Although the study is still ongoing, these initial findings indicate that AI could help radiologists manage workloads in settings where double reading by multiple radiologists is required but staffing may be limited.

Hologic is also showcasing its latest innovations at RSNA, including the AI-powered Genius AI Detection suite of products, breast surgery technologies, and the next-generation Envision Mammography Platform with tilt positioning designed to adapt to patients.³ The company is hosting multiple medical education events throughout the congress, spanning the latest technologies in AI, contrast-enhanced mammography (CEM), and breast surgery.

Hologic’s Genius AI Detection solution is a mammography screening technology designed to locate lesions likely representing breast cancer. Suspicious areas are highlighted at radiologists’ workstations for concurrent reading to support smart, decisive interpretation. Hologic’s deep learning algorithm is fed by the accumulation of a large, diverse patient base, providing rich insight and intelligence.

Hologic Inc. is a global developer of medical technologies that detect, diagnose, and treat health conditions and raise the standard of care worldwide.

References
¹ Report: CSR-00116
² FDA Submission: P080003/S008
³ Hologic data on file: DHM-16430.